Cloud-Native Drug Discovery
Early-Phase Oncology Trials Shaping the Future of Cancer Research
Relatively Speaking
Accelerating Cross-Sector Integration in Pharma and Nutraceuticals
From the “AI Pilot Graveyard” to Enterprise- Grade Impact
EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
.webp)
KNOWLEDGE BANK
-
Articles
Manufacturing mRNA, Cell, and Gene Therapies at Commercial Scale
Why Cell and Gene Therapies Fail in Europe After the Science Has Already Worked The uncomfortable statistic for anyone financing advanced therapies in Europe is not the clinical attrition rate It is the withdrawal rate after approval An analysis of advanced therapy medicinal products granted European marketing authorisation found that roughly one in five had subsequently been withdrawn and of th...
What Are the Implications of the Changing Regulatory Landscape in Europe?
In an age characterized by technological progress changing geopolitical scenarios and an increasing focus on sustainability businesses in Europe are grappling with an intricate network of regulatory shifts
The Future of Oncology Clinical Trials: Adaptive, Biomarker-Led, and AI-Enabled
Oncology now absorbs close to a third of the industrys active development pipeline and a comparable share of its research budget It also carries the worst odds in medicine A molecule entering firstinhuman cancer studies has historically had a midsingledigit probability of reaching approval against roughly double that across other therapy areas For a European chief executive allocating capital acro...
What Is Pharmaceutical Logistics? Top 7 Pharmaceutical Logistics Challenges and Solutions
Pharmaceutical logistics is an important part of the health systems ecosystem and ensures that drugs and medical products that are conscious of patients safely effectively and on time In the core pharmaceutical logistics management includes planning implementation and control of movement and storage of pharmaceutical goods in the supply chain Given the sensitive nature of these products it is nece...
Partnership & Collaboration: The Strategic Force Shaping the Future of Pharmaceutical Growth
The pharmaceutical industry is being reshaped by a simple but powerful reality no company however large or capable can build every capability alone The sector is operating in an environment defined
10 Essential Factors for Selecting a Pharma Publisher in Europe
European pharmaceutical industry is one of the most progressive professional and productive industries in the world As it is understood researchers aspiring to publish novel papers are interested in credible pharma publishers Selecting appropriate publisher increases the visibility of your work and contributes to societal benefit but choosing wrong publisher decreases the value of your work This g...
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
What Are the Implications of the Changing Regulatory Landscape in Europe?
Kate Williamson
The changing regulatory landscape in Europe, spanning data protection, digital services, climate action, finance, healthcare, Brexit impact, consumer protection, AI ethics, taxation, and telecommunica...
-
2
The Future of Oncology Clinical Trials: Adaptive, Biomarker-Led, and AI-Enabled
Lakshmi
Oncology consumes the largest share of pharmaceutical R&D spend yet still carries the industry's steepest attrition curve. A structural shift is now under way: adaptive and platform designs re...
-
3
-
4
Partnership & Collaboration: The Strategic Force Shaping the Future of Pharmaceutical Growth
Deepak Khurana
Strategic partnerships have emerged as the defining growth engine of the pharmaceutical industry. From drug discovery and clinical development to technology transfer and API manufacturing, collaborati...
-
5
10 Essential Factors for Selecting a Pharma Publisher in Europe
Kate Williamson
Selecting the right pharma publisher plays a vital role for any research going into publication in Europe’s rapidly growing pharma market environment. Based on this study, it is possible to defi...
press releases Read more...
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies
Boehringer Ingelheim headquartered in Germany and Sino Biopharmaceutical Limited HK together with its subsidiaries SBP Group today announced a strategic multiprogram option and license agreement to advance potential nextgeneration cancer treatments based on antibodydrug conjugate ADC and Tcell engag...
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
Nxera Pharma Co Ltd announces that its subsidiary Nxera Pharma UK Ltd has entered into an exclusive global license agreement the Agreement with AbbVie Inc AbbVie for Nxeras EP agonist program including NXE a novel small molecule EP receptor agonist discovered
Oryzon announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
Oryzon Genomics SA a clinicalstage biopharmaceutical company and global leader in epigenetics today announced that VIVALDI a Phase Ib pilot study sponsored by CETLAM Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplsicas has been authorized in Spain
Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference
Aarvik Therapeutics Aarvik an innovative ADCfocused biotechnology company dedicated to engineering precision medicines for cancer therapy is pleased to announce important updates to its partnership efforts Dosing of the first patient in a Phase trial in the US for AVPADC
Events Read more...
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
10 - 10
Nov 2026Women in AI
Real Chemistry, 2nd Floor, Lon...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
LATEST NEWS Read more...
Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder
Idorsia Ltd announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to daridorexant for the treatment of insomnia disorder in patients to
Evestia Clinical Acquires Emtex Life Science to Further Enhance its Global Full-Service Clinical Research Capabilities
Evestia Clinical a leading independent global specialist Contract Research Organization CRO today announced the acquisition of Emtex Life Science Emtex a specialist regulatory medical writing company headquartered in Belgium The acquisition strengthens Evestia
UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers today announced that the first patient was dosed with UGN a nextgeneration investigational oncolytic virus The Phase trial will evaluate the safety tolera...
Graviton BioScience and CinRx Pharma Form CinRock Pharma to Advance ROCK2-Targeted Therapies for Cardiovascular Disease
Graviton BioScience Corporation Graviton and CinRx Pharma CinRx today announced the formation of CinRock Pharma CinRock a jointly governed biopharmaceutical company established to accelerate the development of novel ROCKtargeted therapies for patients with cardiovascular diseases
Pretzel Therapeutics Receives UK Regulatory Authorization to Advance PX578 Into Clinical Development in Patients for the Treatment of POLG-Mediated Primary Mitochondrial Disorders
Pretzel Therapeutics Inc a clinicalstage biotechnology company advancing a new class of medicines designed to restore mitochondrial function improve cellular energetics and impede disease progression across a range of neurological and rare diseases today announced that the Medicines and Healthcare p...
TME Pharma Signs Binding Exclusive Negotiation Agreement with Japanese TMS Co., Ltd.
TME Pharma NV Euronext Growth Paris ALTME a biotechcompany with clinical assets for brain cancer and eye diseases is pleased to announce a significant next step in the strategic options for its leading oncology asset NOXA olaptesed pegol
